Wedbush Forecasts Reduced Earnings for Oruka Therapeutics

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Analysts at Wedbush reduced their Q2 2025 earnings estimates for shares of Oruka Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.46) per share for the quarter, down from their previous estimate of ($0.43). Wedbush currently has a "Outperform" rating and a $40.00 target price on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($3.41) per share. Wedbush also issued estimates for Oruka Therapeutics' Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.82) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.05) EPS, FY2027 earnings at ($2.52) EPS and FY2028 earnings at ($3.34) EPS.

Other equities research analysts also recently issued reports about the stock. Wolfe Research assumed coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price target for the company. HC Wainwright reissued a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, February 7th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $39.86.

Oruka Therapeutics Price Performance

ORKA opened at $10.06 on Monday. The company has a market cap of $376.66 million, a price-to-earnings ratio of -1.61 and a beta of 0.25. The firm has a 50 day simple moving average of $9.86 and a 200 day simple moving average of $14.68. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17.

Hedge Funds Weigh In On Oruka Therapeutics

A number of large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. acquired a new position in Oruka Therapeutics during the 1st quarter worth approximately $2,505,000. ADAR1 Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the 1st quarter worth approximately $1,362,000. Braidwell LP raised its stake in shares of Oruka Therapeutics by 37.0% during the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company's stock worth $16,133,000 after purchasing an additional 424,750 shares in the last quarter. OMERS ADMINISTRATION Corp raised its stake in shares of Oruka Therapeutics by 126.8% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 44,900 shares of the company's stock worth $461,000 after purchasing an additional 25,100 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its stake in shares of Oruka Therapeutics by 47.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company's stock worth $5,595,000 after purchasing an additional 176,664 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company's stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.